Astra’s Neogene investment nosedives
NT-125 is discontinued, while two key Datroway readouts are delayed.
Celcuity's $5m pivot does the job
A Pfizer cast-off could become the company's first marketed drug.
Janux tries to improve on the masking approach
Meanwhile, investors await key clinical data.
Nanjing Leads tests investor appetite for Lag3
But BeOne canned its alcestobart deal in May.
5,000 patients later Roche scraps its TIGIT
Tiragolumab failed the Skyscraper-14 and 03 studies, Roche quietly reveals.
